Q2 2022 13F Holders as of 30 Jun 2022
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
62,500,000
-
Total 13F shares
-
53,806,056
-
Share change
-
+130,517
-
Total reported value
-
$2,717,801,258
-
Put/Call ratio
-
41%
-
Price per share
-
$50.51
-
Number of holders
-
211
-
Value change
-
-$14,225,775
-
Number of buys
-
101
-
Number of sells
-
115
Institutional Holders of Blueprint Medicines Corp - Common Stock, par value $0.001 per share (BPMC) as of Q2 2022
As of 30 Jun 2022,
Blueprint Medicines Corp - Common Stock, par value $0.001 per share (BPMC) was held by
211 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
53,806,056 shares.
The largest 10 holders included
PRICE T ROWE ASSOCIATES INC /MD/, VANGUARD GROUP INC, BlackRock Inc., STATE STREET CORP, WELLINGTON MANAGEMENT GROUP LLP, CADIAN CAPITAL MANAGEMENT, LP, JPMORGAN CHASE & CO, MORGAN STANLEY, ALLIANCEBERNSTEIN L.P., and WESTFIELD CAPITAL MANAGEMENT CO LP.
This page lists
212
institutional shareholders reporting positions in this security
for the Q2 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.